Breaking News Instant updates and real-time market news.

GE

General Electric

$8.94

0.435 (5.11%)

, F

Ford

$8.68

-0.035 (-0.40%)

07:35
01/11/19
01/11
07:35
01/11/19
07:35

Unusual call flow in option market yesterday

Notable call activity was cited Thursday in General Electric (GE), Ford (F), Amarin (AMRN), iQiyi (IQ), MGM Resorts (MGM), Rio Tinto (RIO), TransEnterix (TRXC), and Vistra Energy (VST).

GE

General Electric

$8.94

0.435 (5.11%)

F

Ford

$8.68

-0.035 (-0.40%)

AMRN

Amarin

$18.32

3.28 (21.81%)

IQ

iQIYI

$18.16

0.87 (5.03%)

MGM

MGM Resorts

$28.00

0.39 (1.41%)

RIO

Rio Tinto

$50.60

-0.24 (-0.47%)

TRXC

TransEnterix

$2.75

0.01 (0.36%)

VST

Vistra Energy

$24.10

0.79 (3.39%)

  • 15

    Jan

  • 15

    Jan

  • 15

    Jan

  • 16

    Jan

  • 23

    Jan

  • 31

    Jan

  • 25

    Apr

  • 24

    Jul

  • 23

    Oct

GE General Electric
$8.94

0.435 (5.11%)

12/13/18
12/13/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. General Electric (GE) upgraded to Neutral from Underweight at JPMorgan with analyst Stephen Tusa saying he's less negative on the shares with the abating of "known unknowns." 2. Five Below (FIVE) upgraded to Buy from Neutral at Goldman Sachs with analyst Christopher Prykull saying the 18% decline in the stock price over the past month is "disconnected" from the company's robust fundamentals and believes that there is a 20% upside to his price target. 3. Tractor Supply (TSCO) upgraded to Buy from Hold at Deutsche Bank with analyst Michael Baker citing valuation. 4. Procter & Gamble (PG) upgraded to Buy from Neutral at BofA/Merrill with analyst Olivia Tong saying after meetings with CFO Jon Moeller, she believes that the company's early momentum in Q1 of FY19 can be sustained. 5. Dycom (DY) upgraded to Buy from Hold at Craig-Hallum with analyst Christian Schwab saying he believes shares at current levels have become attractive again. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
01/07/19
JPMS
01/07/19
NO CHANGE
Target $6
JPMS
Neutral
JPMorgan sees GE providing something 'more tangible' soon, keeps $6 target
JPMorgan analyst Stephen Tusa says his conversations with clients continue to be dominated by the debate around General Electric's liabilities. The analyst has seen nothing to change his view that $100B of net liabilities and zero enterprise free cash flow is the problem facing management and the right construct when thinking about how to get the story back to "normal" from an equity value standpoint. We are likely approaching the time where GE will provide something "more tangible, perhaps shrinking the balance sheet," Tusa tells investors in a research note. However, related dilution, combined with a full "cleanse" of the accounting structure, should result in a "substantially lower run rate fundamental anchor than many appreciate," says Tusa. He keeps a Neutral rating on GE shares with a $6 price target. The analyst believes Bloomberg's report of Apollo interest in GE's jet leasing business is "not enough value to change" the company's "leverage problem," which he says is "punctuated" by the "collapse in lessor peer multiples."
12/19/18
12/19/18
UPGRADE

Fly Intel: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Medtronic (MDT) upgraded to Overweight from Neutral at JPMorgan with analyst Robert Marcus saying that over the past year he's seen a "significant turnaround in performance" at Medtronic. 2. Masimo (MASI) upgraded to Overweight from Neutral at Piper Jaffray with analyst William Quirk saying management, during recent meetings, was upbeat about their near- and longer-term prospects of driving 8%-10% sales growth, at least 100 basis points of operating margin improvement and the company's 30% operating profit goal. 3. Darden (DRI) upgraded to Buy from Hold at Maxim and to Buy from Neutral at BTIG. 4. Best Buy (BBY) upgraded to Neutral, risks priced in, says MoffettNathanson with analyst Greg Melich saying sales and margin risks are reflected in valuation. 5. General Electric (GE) upgraded to Buy from Hold at Vertical Research. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
12/19/18
VERT
12/19/18
UPGRADE
VERT
Buy
General Electric upgraded to Buy from Hold at Vertical Research
Vertical Research analyst Jeffrey Sprague upgraded General Electric to Buy from Hold with an $11 price target.
F Ford
$8.68

-0.035 (-0.40%)

12/18/18
MSCO
12/18/18
NO CHANGE
Target $10
MSCO
Equal Weight
Ford potential dividend cut could be a buy signal, says Morgan Stanley
Morgan Stanley analyst Adam Jonas said he continues to expect Ford to cut its dividend in half during 2019, but such a potential cut of the dividend could be a buy signal in his view. Such a cut would be a sign that Ford is prepared to make a stronger commitment to sustainable technology than he believes has been demonstrated thus far, Jonas explained. The analyst, who thinks Ford's decisions in the next 6 months could set the tone for the stock over the next several years, also forecasts Ford will undertake a "very significant" restructuring over the next 12 to 18 months that could reduce the size of the company's footprint by more than 25% and include as much as 25,000 headcount cuts. Jonas maintains an Equal Weight rating and $10 price target on Ford shares.
12/14/18
12/14/18
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Tesla (TSLA) initiated with an Outperform at Wedbush and a Hold at Deutsche Bank. 2. New York Times (NYT) initiated with an Outperform at Evercore ISI. 3. Ford (F) and General Motors (GM) were initiated with a Buy at Deutsche Bank, while Autoliv (ALV) was initiated with a Sell. 4. AstraZeneca (AZN) initiated with a Buy at SunTrust while GlaxoSmithKline (GSK) was initiated with a Hold. 5. DaVita (DVA) initiated with an Overweight at Barclays. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
12/13/18
DBAB
12/13/18
INITIATION
DBAB
Deutsche Bank initiates auto sector with cautious view
Deutsche Bank analyst Emmanuel Rosner initiated coverage of the auto sector with a cautious view. Rosner said this view reflects "cyclical and macro risks for the industry across the globe, as well as secular pressure from the shift towards electrified vehicles and autonomous shared mobility." The analyst favors suppliers with "secular growth potential through adoption of their technology," and as such, initiated Aptiv (APTV) and BorgWarner (BWA) with Buy ratings. Rosner also saw value in "suppliers that can maintain organic growth through share gains or favorable end-markets, and have favorable operational track record," and as such, initiated Dana Inc (DAN) and Lear Corporation (LEA) with Buy ratings. The analyst also started General Motors (GM) and Ford (F) with Buy ratings, citing "large potential upside from restructuring and portfolio decisions, favorable product mix and cycle, and value optionality from their efforts in Mobility." Rosner said he was negative on stocks facing secular pressure or market share loss, adding that he sees downside risk in Autoliv (ALV) and Veoneer (VNE), which he initiated with Sell ratings.
12/13/18
DBAB
12/13/18
INITIATION
Target $12
DBAB
Buy
Ford initiated with a Buy at Deutsche Bank
Deutsche Bank analyst Emmanuel Rosner started Ford Motor with a Buy rating and $12 price target.
AMRN Amarin
$18.32

3.28 (21.81%)

12/20/18
JEFF
12/20/18
NO CHANGE
Target $30
JEFF
Buy
Amarin shares will bounce back on 2019 catalysts, says Jefferies
After hosting meetings with management, Jefferies analyst Michael Yee says Amarin represents one of the few "de-risked" standalone blockbuster drugs in the smid-cap Biotech space. Following the stock's pullback from of $23 to $15, Amarin will "bounce and go back up," predicts the analyst. He sees 2019 catalysts from "scripts and sales ramp to FDA approval." Further, a potential takeout is a "wildcard," writes Yee in a note titled "The Big Fish In A Big Pond? Update from Mgmt Meetings..." The analyst keeps a Buy rating on Amarin with a $30 price target.
01/07/19
RHCO
01/07/19
NO CHANGE
Target $15
RHCO
Buy
Amarin price target lowered to $15 from $30 at SunTrust
SunTrust analyst John Boris lowered his price target on Amarin after the company guided its FY19 revenue outlook well below consensus and offered more details timing of Vascepa sNDA filing. The analyst contends that the company needs to employ a larger sales force to "realize Vascepa full potential" beyond the 400 reps currently and also lowers his FY19 EPS view to (23c) from 18c to reflect Amarin's expectations of lower sales and higher SG&A costs. Longer term, Boris keeps his Buy rating on Amarin, noting that Vascepa could have a "significant commercial upside" if it can secure a label for reducing cardiovascular risk.
01/07/19
JEFF
01/07/19
NO CHANGE
Target $30
JEFF
Buy
Jefferies keeps $30 target on Amarin, says guidance conservative
Amarin Friday night reported "strong" Q4 Vascepa results, although stock is trading lower perhaps due to conservative guidance, Jefferies analyst Michael Yee tells investors in a research note. The analyst views the news "as a positive sign of what's been going on recently." Amarin does not even have a label expansion yet and it has been only two months since the mid-November data presentation, Yee writes. He expects trends to continue to grow monthly throughout the year, even before Amarin receives a formal label expansion. While the stock may be down today, "things look strong fundamentally," Yee contends. He views the company's sales guidance as conservative and keeps a Buy rating on Amarin with a $30 price target.
01/08/19
SBSH
01/08/19
NO CHANGE
Target $20
SBSH
Buy
Amarin price target lowered to $20 from $28 at Citi
Citi analyst Joel Beatty lowered his price target for Amarin to $20 after the company's 2019 revenue guidance came in lower than he expected. The analyst, however, continues to view Vascepa as an "attractive and differentiated cardiovascular risk reduction therapy." His peak sales estimate is now $2.5B, down from $3.0B previously.
IQ iQIYI
$18.16

0.87 (5.03%)

10/29/18
EGHT
10/29/18
UPGRADE
EGHT
Hold
iQIYI upgraded to Hold from Sell at 86 Research
12/12/18
HSBC
12/12/18
INITIATION
Target $22
HSBC
Hold
iQIYI initiated with a Hold at HSBC
HSBC initiated iQIYI with a Hold and $22 price target.
12/12/18
12/12/18
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Foamix (FOMX) initiated with a Buy at BofA/Merrill. 2. Jazz Pharmaceuticals (JAZZ) initiated with an Outperform at Oppenheimer while GW Pharmaceuticals (GWPH) was initiated with a Perform. 3. Six Flags (SIX) initiated with a Buy at Berenberg. 4. iQIYI (IQ) initiated with a Hold at HSBC. 5. Intercept (ICPT), Viking Therapeutics (VKTX), and Galmed (GLMD) were initiated with a Buy at B. Riley FBR, while Madrigal Pharmaceuticals (MDGL) initiated with a Neutral. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
10/31/18
FBCO
10/31/18
UPGRADE
FBCO
Outperform
iQIYI upgraded to Outperform from Neutral at Credit Suisse
MGM MGM Resorts
$28.00

0.39 (1.41%)

12/05/18
UBSW
12/05/18
NO CHANGE
UBSW
UBS now sees Macau gross gaming revenue declining in 2019
UBS analyst Robin Farley lowered her 2019 Macau gross gaming revenue forecast to down 1% from up 5% previously. Her 2020 GGR estimate is now up 4% from a prior estimate of up 8%. Despite better than expected revenue in November, likely due to hold fluctuations, the lower estimates are driven by weaker VIP and premium demand amid heightened risk to the macroeconomic outlook in China, Farley tells investors in a research note partially titled "More Visitors Spending Less." She raised her price target for Neutral-rated Wynn Resorts (WYNN) to $113 from $108 while lowering her targets for Neutral-rated MGM Resorts (MGM) to $30 from $32 and Neutral-rated Melco Resorts & Entertainment (MLCO) to $19.50 from $21.60. The analyst also keeps a Neutral rating on Las Vegas Sands (LVS).
01/08/19
JPMS
01/08/19
NO CHANGE
Target $38
JPMS
Overweight
MGM Resorts added to Analyst Focus List at JPMorgan
JPMorgan analyst Joseph Greff added MGM Resorts to his firm's Analyst Focus List saying he sees an increasingly favorable setup for 2019. The analyst raised his price target for the shares to $38 from $35 and keeps an Overweight rating on the name. He sees a combination of relatively low expectations in Las Vegas, improving operations/efficiencies and an attractive valuation.
12/03/18
MSCO
12/03/18
NO CHANGE
MSCO
Overweight
Xi-Trump truce should ease some Macau concerns, says Morgan Stanley
Morgan Stanley analyst Thomas Allen believes that the constructive outcome from the G-20 meeting of Presidents Trump and Xi should be a positive for both Las Vegas Sands (LVS) and Wynn Resorts (WYNN), as he believes a thawing of trade tensions should ease some concerns around Macau concession renewals. Macau stocks have also been weighed down by slowing demand and concerns around the China consumption backdrop, but there have been positive updates on that front too, said Allen, who noted that Las Vegas Sands continues to be his preferred play on Macau. He keeps Overweight ratings on Las Vegas Sands and MGM Resorts (MGM), but does not view MGM as the same type of China proxy given its less than 20% Macau mix. Allen keeps an Equal Weight rating on Wynn shares.
01/03/19
DBAB
01/03/19
NO CHANGE
Target $33
DBAB
Hold
MGM plan to reduce costs positive for shares, says Deutsche Bank
Deutsche Bank analyst Carlo Santarelli says MGM Resorts this morning announced an "enhanced" margin strategy with a plan to reduce costs and improve efficiencies. He views the "MGM 2020" plan as positive for the shares. The analyst has a Hold rating on MGM with a $33 price target.
RIO Rio Tinto
$50.60

-0.24 (-0.47%)

12/18/18
DBAB
12/18/18
NO CHANGE
DBAB
Rio Tinto acquisitions part of Deutsche's 'left-field ideas' for miners
With the potential for slower growth in China, weaker iron ore prices and rising production costs, the Mining industry may consider bold actions in 2019, Deutsche Bank told investors in a research note. The firm's "left-field ideas" include Rio Tinto (RIO) possibly considering acquisitions of Anglo American (NGLOY), First Quantum Minerals (FQVLF) or Freeport McMoRan (FCX). Deutsche also thinks BHP Billiton (BHP) could further look to trim its portfolio with a spinoff that includes its Nickel West unit, oil and gas operations in Australia, and thermal coal in Colombia and Australia.
12/13/18
FBCO
12/13/18
DOWNGRADE
FBCO
Neutral
Rio Tinto downgraded to Neutral from Outperform at Credit Suisse
12/06/18
JPMS
12/06/18
DOWNGRADE
JPMS
Neutral
BHP Billiton downgraded to Neutral from Overweight at JPMorgan
JPMorgan analyst Lyndon Fagan downgraded BHP Billiton (BHP) to Neutral and lowered his price target for the shares to A$35 from A$38. The stock has outperformed Rio Tinto (RIO) by 10% year-to-date, and is now trading "within range of our valuation," Fagan tells investors in a research note. He keeps an Overweight rating on Rio saying the stock is "now cheaper than BHP across a range of valuation metrics."
12/05/18
LYON
12/05/18
UPGRADE
LYON
Buy
Rio Tinto upgraded to Buy from Outperform at CLSA
CLSA upgraded Rio Tinto to Buy from Outperform citing the recent sell-off in shares and a review of Oyu Tolgoi investment agreement.
TRXC TransEnterix
$2.75

0.01 (0.36%)

06/28/18
BTIG
06/28/18
DOWNGRADE
BTIG
Neutral
TransEnterix downgraded to Neutral from Buy at BTIG
BTIG analyst Sean Lavin downgraded TransEnterix to Neutral citing the "rapid" rise in shares.
05/29/18
05/29/18
DOWNGRADE
Target $4

Neutral
TransEnterix downgraded to Neutral with $4 price target at Ladenburg
As previously reported, Ladenburg analyst Jeffrey Cohen downgraded TransEnterix to Neutral from Buy citing valuation with the stock having rallied after the company received FDA approval for expanded indications that now mean the Senhance system is approved for the most commonly performed surgeries in more than 95% of hospitals nationally. Cohen raised his price target for TransEnterix to $4 from $3.50.
11/09/18
LTCO
11/09/18
UPGRADE
Target $4.5
LTCO
Buy
TransEnterix upgraded to Buy from Neutral at Ladenburg
Ladenburg Thalmann analyst Jeffrey Cohen upgraded TransEnterix to Buy while lowering his price target for the shares to $4.50 from $6.
05/29/18
LTCO
05/29/18
DOWNGRADE
LTCO
Neutral
TransEnterix downgraded to Neutral from Buy at Ladenburg
VST Vistra Energy
$24.10

0.79 (3.39%)

05/01/18
SBSH
05/01/18
INITIATION
Target $27
SBSH
Buy
Vistra Energy reinstated with a Buy at Citi
Citi analyst Praful Mehta reinstated coverage of Vistra Energy with a Buy rating and raised his price target for the shares to $27 from $22. Vistra is well positioned to benefit from the market tightening in Texas, Mehta tells investors in a research note. He also expects management to start a dividend, which he feels will help attract a stable investor base.
12/12/18
SBSH
12/12/18
NO CHANGE
Target $32
SBSH
Buy
Vistra Energy shares offer 'significant upside' in 2019, says Citi
Citi analyst Praful Mehta sees "significant upside" for Vistra Energy in 2019 and raised his price target for the shares to $32 from $29. With a power market environment "that is setting up very well," a "significant" amount of capital to allocate towards share buybacks and deleveraging and a "good opportunity" for growth projects, Vistra is a "very good opportunity for 2019," Mehta tells investors in a research note. He reiterates a Buy rating on the shares.
10/25/18
RHCO
10/25/18
UPGRADE
Target $26
RHCO
Buy
Vistra Energy upgraded to Buy at SunTrust on valuation and capital program
As reported earlier, SunTrust analyst Ali Agha upgraded Vistra Energy to Buy from Hold and also raised his price target to $26 from $25. The analyst cites an "attractive entry point" in the stock at current price levels following the recent weakness along with his expectations of a "more aggressive" capital allocation plan in the company's upcoming earnings call. Agha further points to "strong leverage to any improvement in the Texas power market" that would benefit Vistra Energy.
10/25/18
RHCO
10/25/18
UPGRADE
RHCO
Buy
Vistra Energy upgraded to Buy from Hold at SunTrust

TODAY'S FREE FLY STORIES

TCEHY

Tencent

$0.00

(0.00%)

12:59
01/19/19
01/19
12:59
01/19/19
12:59
Periodicals
Tencent not the best opportunity out there right now, Barron's says »

After securing a billion…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BAESY

BAE Systems

$0.00

(0.00%)

12:53
01/19/19
01/19
12:53
01/19/19
12:53
Periodicals
Bae Systems will mount new charge, Barron's says »

Bae Systems has been…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMZN

Amazon.com

$1,696.01

4.01 (0.24%)

, COST

Costco

$213.59

2.15 (1.02%)

12:50
01/19/19
01/19
12:50
01/19/19
12:50
Periodicals
Costco might be 'good buy' following 2018 pullback, Barron's says »

Part of what makes Costco…

AMZN

Amazon.com

$1,696.01

4.01 (0.24%)

COST

Costco

$213.59

2.15 (1.02%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jan

  • 31

    Jan

  • 20

    Feb

  • 03

    Mar

VNO

Vornado

$66.40

1.04 (1.59%)

, KRC

Kilroy Realty

$68.23

0.21 (0.31%)

12:45
01/19/19
01/19
12:45
01/19/19
12:45
Periodicals
Kilroy, Vornado Realty have 'solid' prospects, Barron's says »

Office REITs have been…

VNO

Vornado

$66.40

1.04 (1.59%)

KRC

Kilroy Realty

$68.23

0.21 (0.31%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Feb

GOLD

Barrick Gold

$11.78

-0.11 (-0.93%)

, GG

Goldcorp

$10.37

0.04 (0.39%)

12:41
01/19/19
01/19
12:41
01/19/19
12:41
Periodicals
Gold mining stocks 'an unalloyed bargain,' Barron's says »

Two multibillion-dollar…

GOLD

Barrick Gold

$11.78

-0.11 (-0.93%)

GG

Goldcorp

$10.37

0.04 (0.39%)

NEM

Newmont Mining

$31.77

0.15 (0.47%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

TECH

Bio-Techne

$163.24

1.16 (0.72%)

, A

Agilent

$71.93

1.16 (1.64%)

12:29
01/19/19
01/19
12:29
01/19/19
12:29
Periodicals
Rising demand benefiting Illumina, Thermo Fisher, Barron's says »

Healthy funding and…

TECH

Bio-Techne

$163.24

1.16 (0.72%)

A

Agilent

$71.93

1.16 (1.64%)

DHR

Danaher

$107.43

1.88 (1.78%)

TMO

Thermo Fisher

$240.72

2.55 (1.07%)

ILMN

Illumina

$312.66

2.53 (0.82%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jan

  • 29

    Jan

  • 29

    Jan

  • 30

    Jan

  • 30

    Jan

  • 05

    Feb

ATVI

Activision Blizzard

$48.64

1.26 (2.66%)

, EA

Electronic Arts

$92.50

3.19 (3.57%)

12:22
01/19/19
01/19
12:22
01/19/19
12:22
Periodicals
EA, Activision struggling to survive a Fortnite World, Barron's says »

Netflix (NFLX) delivered…

ATVI

Activision Blizzard

$48.64

1.26 (2.66%)

EA

Electronic Arts

$92.50

3.19 (3.57%)

NFLX

Netflix

$339.20

-14.02 (-3.97%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jan

  • 05

    Feb

  • 12

    Feb

  • 25

    Feb

AIMT

Aimmune

$22.90

0.26 (1.15%)

, CELG

Celgene

$86.27

-0.32 (-0.37%)

09:01
01/19/19
01/19
09:01
01/19/19
09:01
On The Fly
Week in review: How Trump's policies moved stocks »

Catch up on the top…

AIMT

Aimmune

$22.90

0.26 (1.15%)

CELG

Celgene

$86.27

-0.32 (-0.37%)

BIIB

Biogen

$337.46

-0.93 (-0.27%)

CMRE

Costamare

$4.97

0.09 (1.84%)

DAC

Danaos

$0.90

0.05 (5.88%)

DCIX

Diana Containerships

$0.90

-0.02 (-2.17%)

TGH

Textainer

$13.34

0.57 (4.46%)

NM

Navios Maritime

$2.73

-0.04 (-1.44%)

YRCM

Rogers Cantel

$0.00

(0.00%)

EXPD

Expeditors

$69.34

1.43 (2.11%)

LEN

Lennar

$44.11

-0.64 (-1.43%)

KBH

KB Home

$20.30

-0.28 (-1.36%)

PHM

PulteGroup

$26.58

-0.27 (-1.01%)

Z

Zillow

$33.93

0.35 (1.04%)

ZG

Zillow

$33.74

0.35 (1.05%)

RLGY

Realogy

$18.27

-0.155 (-0.84%)

RDFN

Redfin

$18.49

0.48 (2.67%)

DDAIF

Daimler AG

$0.00

(0.00%)

FCAU

Fiat Chrysler

$16.78

0.16 (0.96%)

F

Ford

$8.59

0.23 (2.75%)

GM

General Motors

$38.63

0.35 (0.91%)

HMC

Honda

$29.77

0.22 (0.74%)

NSANY

Nissan

$0.00

(0.00%)

TM

Toyota

$125.40

0.505 (0.40%)

VLKAY

Volkswagen

$0.00

(0.00%)

VC

Visteon

$76.43

4.85 (6.78%)

ADNT

Adient

$19.78

1.59 (8.74%)

AXL

American Axle

$14.62

0.45 (3.18%)

DLPH

Delphi Technologies

$15.94

0.44 (2.84%)

APTV

Aptiv

$72.91

1.77 (2.49%)

BWA

BorgWarner

$40.60

0.54 (1.35%)

LEA

Lear

$151.67

0.98 (0.65%)

TEN

Tenneco

$34.61

1.125 (3.36%)

MGA

Magna

$50.91

0.78 (1.56%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 24

    Jan

  • 25

    Jan

  • 29

    Jan

  • 29

    Jan

  • 31

    Jan

  • 06

    Feb

  • 07

    Feb

  • 14

    Feb

  • 19

    Feb

  • 25

    Apr

  • 18

    May

  • 28

    May

  • 24

    Jul

  • 23

    Oct

ASLN

Aslan Pharmaceuticals

$3.55

(0.00%)

, FPRX

Five Prime

$11.20

0.53 (4.97%)

04:55
01/19/19
01/19
04:55
01/19/19
04:55
Conference/Events
American Society of Clinical Oncology to hold a symposium »

ASCO GI 2019 Symposium…

ASLN

Aslan Pharmaceuticals

$3.55

(0.00%)

FPRX

Five Prime

$11.20

0.53 (4.97%)

KURA

Kura Oncology

$15.70

-0.06 (-0.38%)

ZLAB

Zai Lab

$25.98

-0.05 (-0.19%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

04:55
01/19/19
01/19
04:55
01/19/19
04:55
Conference/Events
Deutsche Bank to hold a conference »

17th Annual dbAccess…

TCCO

Technical Comm Corp

$2.61

-0.19 (-6.79%)

18:02
01/18/19
01/18
18:02
01/18/19
18:02
Hot Stocks
Technical Comm Corp reports notice of failure to satisfy Nasdaq rule »

Technical Communications…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SNAP

Snap

$6.19

0.455 (7.93%)

17:38
01/18/19
01/18
17:38
01/18/19
17:38
Periodicals
Snap exec fired due to undisclosed relationship with consultant, Cheddar says »

Snap's global…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jan

  • 05

    Feb

  • 03

    Mar

SSW

Seaspan

$9.16

0.16 (1.78%)

17:33
01/18/19
01/18
17:33
01/18/19
17:33
Syndicate
Breaking Syndicate news story on Seaspan »

Seaspan files to sell…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TXT

Textron

$49.38

0.75 (1.54%)

17:30
01/18/19
01/18
17:30
01/18/19
17:30
Hot Stocks
Textron subsidiary awarded $439.56M government contract modification »

Bell Helicopter Textron…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jan

TAC

TransAlta

$4.91

0.04 (0.82%)

17:28
01/18/19
01/18
17:28
01/18/19
17:28
Hot Stocks
Mangrove Partners reports 9.4% passive stake in TransAlta »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TDS

Telephone and Data

$36.27

0.42 (1.17%)

17:27
01/18/19
01/18
17:27
01/18/19
17:27
Hot Stocks
Telephone and Data's Meyers sells 80,465 common shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GWPH

GW Pharmaceuticals

$137.24

2.59 (1.92%)

17:03
01/18/19
01/18
17:03
01/18/19
17:03
Syndicate
Breaking Syndicate news story on GW Pharmaceuticals »

GW Pharmaceuticals files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FCSC

Fibrocell Science

$2.03

0.03 (1.50%)

16:55
01/18/19
01/18
16:55
01/18/19
16:55
Syndicate
Breaking Syndicate news story on Fibrocell Science »

Fibrocell Science files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ENLC

EnLink Midstream

$11.75

0.4 (3.52%)

, ENLK

EnLink Midstream Partners

$13.58

0.51 (3.90%)

16:49
01/18/19
01/18
16:49
01/18/19
16:49
Conference/Events
EnLink Midstream Partners to hold a special shareholder meeting »

Special Shareholder…

ENLC

EnLink Midstream

$11.75

0.4 (3.52%)

ENLK

EnLink Midstream Partners

$13.58

0.51 (3.90%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 23

    Jan

FDX

FedEx

$176.97

3.72 (2.15%)

16:49
01/18/19
01/18
16:49
01/18/19
16:49
Hot Stocks
FedEx establishes voluntary buyout program for U.S. workers »

FedEx said in a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Jan

  • 31

    Jan

  • 03

    Mar

  • 19

    Mar

  • 01

    Apr

  • 02

    Apr

ENLK

EnLink Midstream Partners

$13.58

0.51 (3.90%)

, ENLC

EnLink Midstream

$11.75

0.4 (3.52%)

16:48
01/18/19
01/18
16:48
01/18/19
16:48
Conference/Events
EnLink Midstream Companies to hold a special shareholder meeting »

Special Shareholder…

ENLK

EnLink Midstream Partners

$13.58

0.51 (3.90%)

ENLC

EnLink Midstream

$11.75

0.4 (3.52%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 23

    Jan

MKL

Markel

$1,067.03

13.52 (1.28%)

16:36
01/18/19
01/18
16:36
01/18/19
16:36
Hot Stocks
Markel says Anthony Belisle, Alissa Fredricks no longer with company »

Markel Corporation said…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NILSY

Norilsk Nickel

$0.00

(0.00%)

16:35
01/18/19
01/18
16:35
01/18/19
16:35
Downgrade
Norilsk Nickel rating change at Goldman Sachs »

Norilsk Nickel downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JNJ

Johnson & Johnson

$130.65

1.54 (1.19%)

, ABBV

AbbVie

$89.51

2.28 (2.61%)

16:33
01/18/19
01/18
16:33
01/18/19
16:33
Hot Stocks
AbbVie: Phase 3 study of ibrutinib did not meet primary endpoint »

AbbVie (ABBV) announced…

JNJ

Johnson & Johnson

$130.65

1.54 (1.19%)

ABBV

AbbVie

$89.51

2.28 (2.61%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

  • 25

    Jan

  • 27

    Jan

  • 28

    Jan

  • 18

    Feb

  • 18

    May

FOMX

Foamix

$3.70

-0.14 (-3.65%)

16:32
01/18/19
01/18
16:32
01/18/19
16:32
Conference/Events
Foamix to host research and development day »

Research and Development…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 24

    Jan

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.